Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4002692 | 0.67 | — | — | |
| SCHEMBL742732 | 0.66 | — | — | |
| SCHEMBL11765567 | 0.65 | MEN1 (0.32) | MEN1GAAMAPTPABPC1KMT2A | |
| SCHEMBL8085348 | 0.63 | CRBN (0.38) | MEN1GAAMAPTPABPC1KMT2A | |
| SCHEMBL17501887 | 0.62 | PTK2 (0.31) | — | |
| SCHEMBL2447053 | 0.61 | — | — | |
| SCHEMBL8901386 | 0.61 | ALDH1A1 (0.37) | — | |
| SCHEMBL56431 | 0.60 | — | — | |
| SCHEMBL2504471 | 0.60 | — | — | |
| SCHEMBL7807801 | 0.60 | CRBN (0.40) | MEN1GAAMAPTPABPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663227-A2 | DIHYDROPYRIDINE COMPOUNDS FOR TREATING OR PREVENTING METABOLIC DISORDERS | Synta Pharmaceuticals Corporation (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005025507-A2 | DIHYDROPYRIDINE COMPOUNDS FOR TREATING OR PREVENTING METABOLIC DISORDERS | SYNTA PHAMACEUTICALS CORP. (US) | 2005-03-24 | — | — | WO | claimed |
| US-12404304-B1 | Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same | SIERRA SCIENCES, LLC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250179122-A1 | Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same | SIERRA SCIENCES, LLC | 2025-06-05 | — | — | US | disclosed |
| US-11981929-B2 | Use of small molecules to enhance MAFA expression in pancreatic endocrine cells | JANSSEN BIOTECH, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| US-20230227410-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND A PROCESS OF PREPARATION THEREOF | KING ABDULAZIZ UNIVERSITY (SA) | 2023-07-20 | — | — | US | disclosed |
| US-20210079353-A1 | USE OF SMALL MOLECULES TO ENHANCE MAFA EXPRESSION IN PANCREATIC ENDOCRINE CELLS | JANSSEN BIOTECH, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| US-10006006-B2 | Use of small molecules to enhance MAFA expression in pancreatic endocrine cells | JANSSEN BIOTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| CN-106966974-A | A kind of preparation method of quinoline | 上海应用技术大学 | 2017-07-21 | — | — | CN | disclosed |
| US-20150329828-A1 | Use of Small Molecules to Enhance Mafa Expression in Pancreatic Endocrine Cells | JANSSEN BIOTECH, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| EP-1307429-B1 | PROCESS FOR ASYMMETRIC SYNTHESIS OF SUBSTITUTED 1,4-DIHYDROPYRIDINES | ASTRAZENECA AB (SE) | 2007-11-28 | — | — | EP | disclosed |
| EP-0665834-B1 | QUINOLONE AND ACRIDINONE DERIVATIVES FOR THE TREATMENT OF URINARY INCONTINENCE | ASTRAZENECA AB (SE) | 2001-05-30 | — | — | EP | disclosed |
| US-6121284-A | SPECIFIED 1-(ALKYL OR CYCLOALKYL)-2-METHYL-3-(ALKOXYCARBONYL)-4-(SUBSTITUTED PYRIDYL OR ARYL)-5-OXO-1,4,5,6,7,8-HEXAHYDROQUINOLINE COMPOUNDS; TREATING SICKLE CELL ANEMIA, PSYCHOSES, DEPRESSION | BAYER AKTIENGESELLSCHAFT (DE) | 2000-09-19 | — | — | US | disclosed |
| US-5622964-A | ADMINISTERING 4,6,7,8-TETRAHYDRO-5(1H)-QUINOLONE DERIVATIVE TO TREAT ASTHMA IN MAMMALS | ZENECA LIMITED (GB) | 1997-04-22 | — | — | US | disclosed |
| EP-0755382-A1 | QUINOLONE DERIVATIVE FOR TREATMENT OF URINARY INCONTINENCE | ZENECA LIMITED (GB) | 1997-01-29 | — | — | EP | disclosed |
| EP-0705830-A1 | 2,3-Cyclic condensed 1,4-dihydropyridines, process for their preparation and their use as K-channel modulators | BAYER AG (DE) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995028388-A1 | QUINOLONE DERIVATIVE FOR TREATMENT OF URINARY INCONTINENCE | ZENECA LIMITED (GB) | 1995-10-26 | — | — | WO | disclosed |
| US-5455253-A | For urinary incontinence | ZENECA LIMITED (GB) | 1995-10-03 | — | — | US | disclosed |
| EP-0665834-A1 | QUINOLONE AND ACRIDINONE DERIVATIVES FOR THE TREATMENT OF URINARY INCONTINENCE | ZENECA LIMITED (GB) | 1995-08-09 | — | — | EP | disclosed |
| WO-1994008966-A1 | QUINOLONE AND ACRIDINONE DERIVATIVES FOR THE TREATMENT OF URINARY INCONTINENCE | ZENECA LIMITED (GB) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179122-A1 | Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same | TERT, RNGTT, TERF2 | MEN1 3080/4885GAA 833/4885MAPT 1751/4885 |
| US-12404304-B1 | Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same | TERT, TELO2, POT1 | MEN1 4306/4885GAA 3170/4885MAPT 2646/4885 |
| US-20230227410-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND A PROCESS OF PREPARATION THEREOF | CBR3, SQOR, RECQL | MEN1 3102/4885GAA 4078/4885MAPT 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.